Next Article in Journal
Development of a Medication-Related Osteonecrosis of the Jaw Prediction Model Using the FDA Adverse Event Reporting System Database and Machine Learning
Next Article in Special Issue
Therapeutic Potential of Qilianxiaopi Formula: Targeting ADAM17-Mediated Chronic Inflammation in Atrophic Gastritis
Previous Article in Journal
Enhanced Intranasal Delivery of Atorvastatin via Superparamagnetic Iron-Oxide-Loaded Nanocarriers: Cytotoxicity and Inflammation Evaluation and In Vivo, In Silico, and Network Pharmacology Study for Targeting Glioblastoma Management
Previous Article in Special Issue
Cardioprotective Effects of Ferulic Acid Through Inhibition of Advanced Glycation End Products in Diabetic Rats with Isoproterenol-Induced Myocardial Infarction
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Vatairea Genus as a Potential Therapeutic Agent—A Comprehensive Review of Ethnobotanical, Phytochemical, and Pharmacological Properties

by
Sarah Andrade Toledo
,
Laryssa Danielle da Silva Reis
,
Brenda Costa da Conceição
,
Lucas Villar Pedrosa da Silva Pantoja
,
Fábio José Coelho de Souza-Junior
,
Flávia Cristina Santos Garcez
,
Cristiane Socorro Ferraz Maia
and
Eneas Andrade Fontes-Junior
*
Laboratory of Pharmacology of Inflammation and Behavior, Institute of Health Sciences, Federal University of Pará, Belém 66075110, Brazil
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(3), 422; https://doi.org/10.3390/ph18030422
Submission received: 1 December 2024 / Revised: 7 March 2025 / Accepted: 12 March 2025 / Published: 17 March 2025
(This article belongs to the Special Issue Therapeutic Potential of Natural Products in Internal Diseases)

Abstract

:
The Vatairea genus (Fabaceae family) is widespread in the Amazon rainforest. Some species of this genus are known for their ethnobotanical significance and biological potential. The present study explores the pharmacological and promising therapeutic activities, ethnobotanical profile, and phytochemical prospection of Vatairea sp., a monophyletic group of flowering plants, which includes economically and culturally important genera due to their diverse uses, including medicinal applications. V. lundellii, V. guianensis, V. erythrocarpa, V. fusca, V. heteroptera, V. paraensis, V. sericea, and V. macrocarpa are included in the Vatairea sp., also recognized for its high wood quality and potential medicinal properties. Studies show significant antibacterial activity in V. guianensis extracts against Gram-positive and Gram-negative bacteria, whereas V. macrocarpa lectin exhibits broad-spectrum antibacterial effects, including modulation of antibiotic resistance. Additionally, V. macrocarpa and V. guianensis have demonstrated antifungal properties, with compounds like Vatacarpan exhibiting potent activity against Candida sp. In vivo studies highlight the neurotoxic effects of V. macrocarpa lectin, suggesting a dual role in the central nervous system. Despite these findings, research on Vatairea’s toxicological aspects is limited, with only a few studies on V. macrocarpa and V. guianensis extracts indicating a need for further exploration of this genus’ pharmacological and therapeutic potential.

Graphical Abstract

1. Introduction

Traditional medicine has supplied a foundation for pharmacology for decades, contributing to drug discovery and development. The Amazon rainforest, rich in biodiversity and folk medicine, is a crucial resource for discovering bioactive compounds [1].
In Amazon plants, the Vatairea genus has received significant prominence. The genus is a non-endemic common plant in Brazil, composed of eight species and classified in the family Leguminosae (Fabaceae). Vatairea sp. is also present in other Amazon countries, such as Peru, Venezuela, and Colombia. Plants of Vatairea sp. are popularly known as amargoso (bitter), angelim-amargoso (bitter angelim), angelim-do-igapó, guáboa, angelim [2]. In traditional communities, these botanical species’ heartwood and bark are prepared by maceration and utilized for gastrointestinal diseases, insulin control, and other functions; however, solely two of the eight species have been studied for pharmacological activities (i.e., V. guianensis and V. macrocarpa). Their ethnopharmacological therapeutic uses in Brazil involve treating digestive and circulatory systems diseases [3,4].
This comprehensive review aims to systematize the existing knowledge and provide an in-depth and critical analysis of the genus Vatairea, highlighting its pharmacological and therapeutic potential, ethnobotanical significance, and phytochemical properties. Our pioneering approach also highlights existing gaps, providing insights into future research. For this purpose, studies on PubMed, Scopus, and Web of Science platforms were selected without language restrictions. The scientific names of the Vatairea species and their scientific synonyms (World Flora Online database) were used as search keys. Articles related to the plant’s therapeutic, pharmacological, ethnobiological, and phytochemical aspects were selected.

2. Ethnobotanical Features

2.1. Taxonomy and Botanical Aspects

Recognized as the most diversified family in terms of Brazilian flora and one of the largest angiosperm families, the Fabaceae family comprises 19,325 species divided into 727 genera worldwide, with 2807 species across 222 genera found in Brazil [5]. The Fabaceae family is also a monophyletic group of flowering plants, popularly known as leguminous, ranging from trees to shrubs. It plays a pivotal role in nitrogen fixation through its relationship with the soil. The family is divided into three subfamilies: Caesalpinioideae, Mimosoideae, and Faboideae [6]. Some genera within the Fabaceae family stand out for economic and cultural reasons due to their high diversity and versatile uses, ranging from food and construction to medicinal purposes [7].
Vatairea is one of the primary genera in the family, known for its neotropical origin and excellent wood quality, comprising eight species: Vatairea lundellii, V. erythrocarpa, V. fusca, V. guianensis, V. heteroptera, V. macrocarpa, V. paraensis, and V. sericea [8] (Figure 1). These species share some similarities, such as spirally grouped leaves at the top of their branches and petals ranging from shades of blue to purple, with their primary life form being trees [9]. The genus has garnered scientific interest due to its diverse applications, including its potential medicinal uses, reflecting the significant subject for this comprehensive review.
V. heteroptera is endemic to Brazil and unique in distribution in the Atlantic Forest. It is also a predominantly large tree, averaging 20–30 m in height, and heartwood tends towards brown, with a trunk that has barely perceptible sapwood at the beginning. V. erythrocarpa grows more towards the central side of the Amazon. It presents a red epithet commonly over 20–30 m tall, with a more yellowish-brown interior [8].
V. fusca also varies between 20 and 30 m in height, with its brown heartwood, seed, and embryo difficult to identify. Such species are abundant in the lower Amazon region and southern Pará state. V. lundellii is over 20 m tall, with yellowish-brown heartwood, and blooms relatively during drier periods, such as January to March, with its fruit growing soon afterward. Its geographical occupation is also characteristic of southern Mexico, predominantly in rainforests [8].
V. guianensis is recurrent throughout the Amazon River region, accompanied by floodplain forests; it is of medium size, 8–25 m; has easy recognition through the size of its flowers, which reach up to 3.5 cm; and huge sapopemas at the beginning of the trunk, being considered the most geographically distributed. V. macrocarpa is 5–12 m high, geographically native with greater predominance in the Brazilian Cerrado region. This plant presents a slightly thinner bark, associated with a brown heartwood, and enormous phenotypic plasticity, with specific variations related to the soil [8].
V. paraensis, the largest tree (30–40 m in height) in the Vatairea genus, presents huge sapopemas on the trunk base and rougher bark, resembling V. fusca. Other trees differ from this, however, due to its more turbocharged hypanthus [8]. Finally, predominantly located in the rainforest, V. sericea is also a large tree (20–40 m), with uncommonly sharper leaflets, small sapopemas on the trunk, a rougher surface, and more yellowish heartwood [8].

2.2. Distribution and Traditional Uses

Vatairea sp. are native to Brazil and endemic in Guyana and the Atlantic coast of Central America and Mexico [8]. In Brazil, the species are found in the Amazon (V. erythroderma, V. fusca, V. guianensis, V. macrocarpa, V. paraensis, and V. sericea), Cerrado, Caatinga (V. macrocarpa), and in the Atlantic Forest (V. heteroptera and V. lundellii) [8,12].
Plants of the genus are commonly known in Brazil as ‘faveira’, ‘fava’, ‘fava-amarela’, ‘sucupira’, ‘sucupira-amarela’, ‘sucupira-preta’, ‘sucupira-amargosa’, ‘bittersa’, ‘andiroba-amargos’, ‘angelim-de-igapó’, ‘angelim’, ‘angelim-amargoso’, ‘angelim-do-cerrado’, ‘pau-roxo’ (Figure 2) [2,13].
According to ethnopharmacological information, plants of the Vatairea genus are universally used for dermatological treatments. V. guianensis is used in the form of juice, tincture, or maceration of the fruit, bark, stem, or root, to treat superficial mycoses and skin diseases [13,14,15,16]. It also corresponds to the most cited species in the reviewed literature, accompanied by the species V. macrocarpa and V. lundellii, which also have antimicrobial potential [16,17,18,19,20,21,22].
Anti-inflammatory and antiproliferative activities have also been associated with the V. guianensis and V. macrocarpa species [22,23,24,25]. V. macrocarpa also helps to control diabetes and treat stomach problems [23,26,27,28].
Thus, the eight species of Vatairea, native to Brazil, often have similar popular names and applications in traditional medicine, related to treating infections and inflammatory processes, but also applied to treating endocrine diseases. The preparation forms observed are also diverse, including juices, tinctures, teas, and macerations, which may indicate different solubility patterns to the diverse medicinal properties reported by traditional people [2,4,13,22,23,24].

3. Phytochemical Aspects

Only three of eight Vatairea species were subjected to phytochemical studies, namely V. guianensis, V. macrocarpa, and V. heteroptera, whose findings are summarized in Table 1 and are discussed below.

3.1. Vatairea guianensis

Simatupang et al. [29] conducted an illuminating phytochemical investigation of V. guianensis to identify potential chemical compounds related to the skin-irritating effects of the wood derived from this species. It is worth highlighting that species of the genus Vatairea have significant economic value due to the commercialization of trunk wood, which was extensively exported to Europe in past decades. Simatupang and colleagues [29] identified three anthrone compounds in the benzene extract of the heartwood of V. guianensis for the first time, namely chrysophanic acid-9-anthrone, physcion-9-anthrone, and physcion-10-anthrone (Table 1). Some anthrone derivatives have been shown to cause skin irritation [32].
Following Simatupang et al. [29]’s study, Piedade and Wolter Filho [14] identified a new anthraquinone from V. guianensis, called physcion. The authors employed a different phytochemical approach, using a hot extraction with a Soxhlet apparatus to obtain an ethanolic extract, fractionated with organic solvents (e.g., hexane, benzene, and methanol). The benzene fraction allowed the isolation of physcion, chrysophanol, emodin, and dihydromacarfinic acid (a triterpene compound). This successful phytochemical approach led to the isolation of significant quantities of these compounds (Table 1).
The first phytochemical study with the species V. guianensis was published only in 2011, based on the essential oil of its fruits. Chemical analysis identified the prevalence of aldehydes and carboxylic acids, including docosahexaenoic acid (DHA), an omega-3 fatty acid known for its role in neurodevelopment [18,33]. On the other hand, analysis of the ethanolic extract demonstrated the presence of anthraquinone compounds, chrysophanol, and physcion, confirming the previously identified species [18].
In addition, four new isoflavonoid compounds from V. guianensis leaves were identified: 5,3′-dihydroxy-4′-methoxy-2″,2″-dimethylpyrano-(5″,6″:8,7)-isoflavone, 5,7-dihydroxy-3′,4′-methylenedioxy-8-prenyl-isoflavone, 5,3′-dihydroxy-4′-methoxy-7-O-β-glucopyranoside-8-prenyl-isoflavone, and derrone [19]. The authors suggested that this phytochemical profile was closely related to the significant antioxidant properties exhibited by this plant. In this context, Souza and coworkers [30] also assessed the chemical profile of the ethanolic extract of V. guianensis, investigating the sapwood part. Fractionation of the ethanolic extract with hexane yielded the isolation of chrysophanol, physcion, formononetin, bolusantol D, betulinic acid, sitosterol, and stigmasterol. It is important to highlight that formononetin and bolusantol D had been previously reported for species of the Fabaceae family, but this was the first report of their occurrence in the Vatairea genus.
The most recent scientific report on the phytochemical profile of V. guianensis was also conducted by Souza and colleagues [22]. In a scenario focused on flavonoid identification, they revealed a novel isoflavonoid obtained from the ethanolic extract of V. guianensis leaves, which was fractionated with ethyl acetate. The identified isoflavonoid compounds were 5,7,3′-trihydroxy-4′-methoxy-8-prenyl-isoflavone (a new compound identified in the species), lupiwighteone, and 5,7,4′-trihydroxy-3′-methoxy-8-prenylisoflavone.
Albeit lectins are not part of the secondary metabolism in plants, their pivotal role in biological systems has increased scientific interest, particularly in species of the genus Vatairea. Remarkably, these proteins can recognize and bind to specific carbohydrates, mediating essential immunological processes such as pathogen defense and cell signaling. Lectins are present in plants and animals and can have various applications in medical research, such as in diagnosis, antiviral, antitumor drugs, and drug delivery systems [34,35,36,37]. Thus, new lectins with benefits in these areas have been extensively investigated. Lectins from the Vatairea genus, specifically V. guianensis, have been successfully isolated and studied, revealing key structural and functional properties. The V. guianensis lectin exhibits high thermal stability and remains stable across all-around acidic and basic pH levels. Its glycoprotein structure resembles known lectins, including V. macrocarpa [38,39].

3.2. Vatairea macrocarpa

The limited phytochemical investigations of V. macrocarpa reveal a predominant presence of phenolic compounds, particularly catechin, epicatechin, kaempferol-3-O-α-l-rhamnopyranoside, tannins, and other phenolic substances [23]. Santana et al. [19] conducted a comprehensive phytochemical analysis, preparing eight extracts from various parts of the plant using hexane, ethyl acetate, and ethanol as solvents. The extracts were obtained from root wood (hexane and ethyl acetate), root bark (ethyl acetate), stem wood (hexane, ethyl acetate, and ethanol), stem bark (ethyl acetate), and leaves (ethyl acetate). From the ethyl acetate extract of the root bark, several compounds were isolated following fractionation with hexane, ethyl acetate, and methanol. Notably, a new pterocarpan was identified and named Vatacarpan by the authors, along with musizin, a naphthoquinone previously reported in the literature.
The lectin from V. macrocarpa has also been a focus of the investigation. This lectin was identified with a 22 kDa N-terminal sequence, a structural feature comparable to other endogenous protein fragments, suggesting potential shared functional roles [38,39].

3.3. Vatairea heteroptera

Formiga et al. [30] investigated the phytochemical composition of V. heteroptera, focusing on the trunk wood, which was extracted using benzene. The study identified several key compounds: chrysophanol, sitosterol, stigmasterol, emodin, (2S)-7-hydroxyflavone, and formononetin. This report is notable for being the first to document phytochemicals with potential medicinal value in the genus Vatairea. Specifically, the study identified anthraquinones (chrysophanol and emodin), flavonoids ((2S)-7-hydroxyflavone and formononetin), and triterpenoids (sitosterol and stigmasterol) in the genus.
Thus, there is a marked lack of information on the phytochemical composition of Vatairea sp. In the few studies carried out, aldehydes and carboxylic acids (essential oil) were identified: lectins (seeds) [18,40,41,42], which will be discussed in more detail later, given the interest in the literature on these substances; anthraquinones, flavonoids, triterpenes, and tannins (extracts from various parts of plants), related to the antioxidant potential of some of these species [14,19,22,24,30]. These elements need to be further investigated, and new studies need to be conducted to increase knowledge of these species’ potential and the safety of their use.

4. Pharmacological Properties

There are limited studies on the safety of using Vatairea species for therapeutic purposes. Despite this, its effects on microorganisms and diseases related to the central nervous, endocrine, immune, cardiovascular, and renal systems have already been explored. The investigation, however, is still in its initial stages. Studies related to the biological properties of Vatairea species are summarized in Table 2 and will be discussed below.

4.1. Toxicity Studies

As mentioned above, only two species (V. macrocarpa and V. guianensis) have been evaluated for their toxicity. V. macrocarpa leaves’ ethanolic extract did not show cytotoxicity in neutrophils culture [24]. No adverse effects in rodents, such as relevant behavioral changes or deaths, were observed at subchronic doses [44]. On the other hand, the lectin from V. macrocarpa showed in vitro cytotoxicity in human lymphocytes at concentrations above 0.5 µM and demonstrated genotoxicity at concentrations above 8.0 µM [43].
For V. guianensis, the hydroethanolic extract obtained by maceration showed no acute oral toxicity at doses below 2000 mg/kg [16]. Thus, the studies indicate that extracts of V. macrocarpa and V. guianensis are relatively safe, noting that they only cover in vitro tests and murine models. It is also important to highlight the cytotoxic and genotoxic effects of the V. macrocarpa lectin. Therefore, there is a need for more in-depth investigations to validate the safety of its use, since they are widely used in traditional medicine. It is also important to highlight the need to investigate the toxicity of the other six species of the genus, for which no studies were identified.

4.2. Pharmacological Studies

Although the Vatairea genus comprises diverse species, most studies investigating pharmacological activity primarily focused on V. macrocarpa and V. guianensis. Numerous models have been used to investigate their pharmacological activities and therapeutic potential. In vitro studies gathered findings that underscore the importance of studying medicinal plants, such as, in this case, species of the Vatairea genus.
It is noted that predominantly in vivo studies have demonstrated the pharmacological activities derived from various species of the genus Vatairea. Molecules such as lectins, found in several species including V. macrocarpa and V. guianensis, present numerous opportunities for modulating biological systems [52].

4.2.1. Antibacterial Activity

Antibacterial activity of several V. guianensis extracts (e.g., hydroalcoholic, hexane, chloroform, and methanolic) against Gram-positive (Staphylococcus aureus and Enterococcus faecalis) and Gram-negative (Pseudomonas aeruginosa and Salmonella sp.) bacteria have been reported [45]. All extracts demonstrated such activity, with minimum inhibitory concentration (MIC) ranging from 3.12 to 50 µg/mL and minimum bactericidal concentration (MBC) ranging from 6.25 to 100 µg/mL. Additionally, Oliveira et al. [17] confirmed the effectiveness of V. guianensis against S. aureus, further supporting its antibacterial properties.
Anthraquinones are well-documented for their significant antimicrobial potential [53]. Within the Vatairea genus, particularly in V. guianensis, notable anthraquinone compounds such as chrysophanol, physcion, and their derivatives have been identified, likely contributing to the antimicrobial activity reported [22,30,31]. Physcion, a natural anthraquinone derivative, exhibits remarkable antibacterial activity against S. aureus, S. epidermidis, and P. aeruginosa. At the same time, chrysophanol has also been consistently highlighted for its potent antimicrobial properties against various bacterial and fungal strains [54,55,56]. These findings revealed how phytochemical investigations are essential for advancing pharmacological research on natural products, as they enable the identification of bioactive compounds and provide critical insights into their therapeutic potential, paving the way for the discovery of novel antimicrobial agents.
Unlike V. guianensis, for which research focuses on antibacterial activity in extracts, V. macrocarpa has been extensively studied for its lectin, a protein extracted from the seed. Vasconcelos et al. [40] demonstrate the broad-spectrum antibacterial activity of V. macrocarpa lectin against several pathogens, including S. epidermidis, S. aureus, Klebsiella oxytoca, and P. aeruginosa. Similarly, Teixeira [41] found that lectins from different plant species, including V. macrocarpa, reduced the adhesion of Streptococcus sp. to the salivary components of dental plaque. These findings suggest that the V. macrocarpa lectin, like the lectins from other species, can disrupt bacterial adhesion, potentially preventing biofilm formation. This potential antibacterial activity of V. macrocarpa seed lectins was tested against multi-drug-resistant bacteria strains of S. aureus and E. coli [42]. The V. macrocarpa lectin demonstrated the ability to modulate antibiotic activity [57]. When combined with antibiotics, such as gentamicin, norfloxacin, and penicillin, the lectin increased the effectiveness against S. aureus, but not against E. coli [42]. In silico predictions suggest that this interaction between the lectin and gentamicin involves residues within the lectin’s carbohydrate-binding site [58]. This finding reinforces the potential of V. macrocarpa lectins as a promising strategy for combating multi-resistant bacteria.

4.2.2. Antifungal Activity

In addition to antibacterial properties, V. guianensis and V. macrocarpa have also been explored for their antifungal potential. Santana et al. [20] investigated in vitro the antifungal activity of several Fabaceae species, including V. macrocarpa. In this study, the authors explore the ethyl acetate extract of V. macrocarpa and evaluate fractions and isolated compounds. Notably, the isolated compound vatacarpan demonstrated significant in vitro activity against Candida albicans (MIC = 0.98 µg/mL), a remarkably low concentration compared to established antifungal drugs, such as fluconazole and amphotericin B. This finding highlights the potential of V. macrocarpa as a source for developing new antifungal agents. Recently, in a study on antifungal activity focusing on V. guianensis, Souza et al. [22] isolated a new compound, 5,7,3′-trihydroxy-4′-methoxy-8-prenylisoflavone, from leaves, and evaluated its antifungal properties. The authors employed the ethanolic extract of V. guianensis leaves against several Candida species, including C. dubliniensis, C. albicans, C. parapsilosis, and C. krusei. The results demonstrated the antifungal activity of the extract against C. dubliniensis, C. albicans, and C. krusei. Remarkably, the extract fraction exhibited significant activity against all fungi investigated, while the isolated compound showed more potent activity against C. parapsilosis and C. dubliniensis.
The evidence gathered demonstrates the potential of V. macrocarpa and V. guianensis for treating infectious conditions, presenting a broad spectrum of action, combating bacteria and fungi, and enhancing the activity of conventional antibiotics. These findings are interestingly aligned with the traditional use of these plants to treat skin diseases, conditions that can be explored in in vitro and murine models, to expand the pharmacological characterization of the species and elucidate its potential benefits [52]. No studies were identified regarding the possible antibiotic properties of the other Vatairea species, highlighting yet another gap that must be filled.

4.2.3. Endocrine System

Among the species of the Vatairea genus, V. macrocarpa stands out for its endocrine-modulating effects. In streptozotocin-challenged rats, ethanolic extracts of V. macrocarpa demonstrated significant anti-diabetic activity by improving insulin resistance, with authors suggesting a possible modulation of pancreatic beta-cell function [26]. A recent study employing refined pharmacological techniques found that V. macrocarpa stem bark ethanolic extract attenuated diabetes-like parameters by reducing glycemia, urinary glucose, and urea levels. The extract improved insulin signaling by enhancing GLUT4 receptor translocation to the cell membrane and decreasing phosphoenolpyruvate carboxykinase (PEPCK) activity, thereby reducing gluconeogenesis [27]. These findings, combined with the phenolic-rich composition of V. macrocarpa, highlight its potential as a source of endocrine-active compounds.

4.2.4. Cardiovascular and Renal Systems

V. macrocarpa galactose-binding lectin from seeds significantly increases perfusion pressure, renal vascular resistance, urinary flow, and glomerular filtration rate, not altering the tubular transport of sodium, potassium, or chloride in isolated Wistar rats’ kidneys [46]. Pretreatment with a lectin–galactose complex blocked these renal parameters’ increase, suggesting that the lectin specifically interacts with carbohydrate-binding sites in the renal system. Additionally, kidneys treated with the lectin showed moderate deposits of proteinaceous material in the tubules and urinary space, while those pretreated with the lectin–galactose complex showed only small amounts of this material, with no abnormalities in the renal tubules. These results indicate that V. macrocarpa lectin significantly affects renal function, modulated by its interaction with carbohydrates [46].
V. guianensis lectin exhibits vasorelaxant ex vivo activity in contracted rat aortas. This effect is strictly endothelium-dependent and involves nitric oxide production and the lectin domain [38]. Interestingly, despite the structural similarity, V. macrocarpa and V. guianensis lectins demonstrated divergent effects on the vascular bed. V. macrocarpa lectin demonstrated vasoconstrictive properties on the renal artery, whereas V. guianensis lectin exhibited a vasorelaxant effect on the aorta. This peculiarity should be further explored to elucidate the structure–activity relationship and the mechanisms that trigger such effects [38,46].

4.2.5. Immune System

Anti-inflammatory properties of the ethanolic leaf extract of V. macrocarpa in experimental in vitro models were also described. The extract exhibits phenolic compounds and flavonoids, such as catechin, epicatechin, and kaempferol-3-O-a-l-rhamnopyranoside. The in vivo model was effective in reducing leukocyte migration and protein exudation in carrageenan-induced pleurisy, as well as inhibiting inflammatory parameters in models of persistent paw inflammation and bacillus Calmette–Guérin (BCG)-induced pleurisy. These findings suggest that V. macrocarpa extract has potential as a natural agent for treating inflammatory diseases [24].
Interestingly, Alencar et al. [47] showed that V. macrocarpa seed lectins can induce an inflammatory response. The lectin was injected into the peritoneum of rats to investigate how it triggers this effect, resulting in increased neutrophil migration into the peritoneal cavity. However, adding α-D-galactose to the lectin solution partially inhibited this effect. Neutrophil migration was also reduced when the peritoneal cavity was depleted from resident cells previously, suggesting an indirect mechanism of neutrophil migration, possibly mediated by resident macrophages. The authors propose that galactose-binding lectins’ effects are not linked to inflammatory mediators like lipoxygenase, cyclooxygenase, or platelet-activating factor (PAF). On the other hand, they observed that dexamethasone and thalidomide reduce lectin-induced neutrophil migration, indicating the possible involvement of cytokines in their proinflammatory effects [47].
Furthermore, aiming to confirm their hypothesis of the involvement of macrophage signaling in the proinflammatory effect of lecithin, Alencar et al. [48] injected V. macrocarpa seed lectin into a primary culture of rat macrophages. The culture supernatant was collected and injected into rats’ peritoneal cavities, increasing neutrophil migration proportionally to the lectin concentration. They therefore concluded that V. macrocarpa seed lectin can induce cultured macrophages to release a neutrophil chemotactic mediator. These findings highlight the V. macrocarpa seed lectin as an important tool for studying pathological conditions associated with excess leukocytes at inflammatory sites causing tissue damage [48]. This also demonstrates an important divergence between the anti-inflammatory effects promoted by the V. macrocarpa leaf extract and the proinflammatory effects induced by the seed lectin [24,47,48].
Still investigating the proinflammatory property of lectin, this time obtained from V. guianensis seeds, Marques et al. [49] administered it to the rat’s paws, observing the formation of edema in a time- and dose-dependent manner. The researchers suggest that V. guianensis lectin binds to specific glycans on targets, triggering inflammatory responses. The COX inhibitor indomethacin and interleukin-1β inhibitor thalidomide partially blocked the edematogenic effect, while the NOS inhibitor L-NAME did not. While pointing to the involvement of prostaglandins and interleukins in lectin-induced edema, this finding excludes the nitric oxide pathway, contrasting with its vasorelaxation mechanism previously discussed [38,49].

4.2.6. Central Nervous System

Notably, lectins are the most studied molecules in glycobiology, and plant lectins can serve as important tools for studying the role of carbohydrate–protein interactions in cellular function modulation. In the central nervous system (CNS) context, it was recently demonstrated that the V. macrocarpa seed lectin can alter neural function, eliciting depressive effects and activating neuroinflammatory markers [50]. The study highlights that although it has a carbohydrate affinity, like galactose-1 (gal-1), the lectin can exert neurotoxic effects in the hippocampus of mice, in contrast to the neuroprotective action already reported for gal-1. These findings suggest a possible dual role of galactose-binding lectins in the modulation of CNS function [50]. Lectins can be utilized in both basic and applied research, offering new alternatives for understanding neurological diseases, such as mental disorders, neurodegenerative diseases, and neuro-oncological conditions, as well as driving the search for new therapies for the diagnosis and treatment of these conditions [50,52].

4.2.7. Nociception

Leite et al. [51] studied the effects of V. macrocarpa lectin on nociception using menthol- or capsaicin-induced orofacial pain models in zebrafish, the only identified study of this activity for the genus. However, V. macrocarpa seed lectin pretreatment failed to demonstrate orofacial antinociception [51].

4.2.8. Wound-Healing

Research on the wound-healing properties of V. guianensis has demonstrated its potential to modulate the healing process by affecting the inflammatory response’s intensity and promoting collagen synthesis pathways. This capability indicates that compounds found in the plant may influence tissue regeneration and decrease inflammation related to the healing process [16]. This effect would not be linked only to the pro/anti-inflammatory effect, but also to the antioxidant and antimicrobial activities of the plants. The correlation between these aspects suggests that the modulation of the inflammatory response by V. guianensis during the healing process may be partly mediated by the interaction of lectin with glycans on lesioned tissues. This interaction influences the production of essential inflammatory mediators for the initial response to injury that regulates the synthesis of structural components such as collagen, which is crucial to adequate scar tissue formation [16,49]. These hypotheses should be tested in the future, as they may contribute to developing new therapeutic agents and a better understanding of scar modulation strategies.

5. Final Considerations

This review is the first to highlight the potential of the Vatairea genus, which is utilized in traditional Amazonian medicine and systematizing knowledge about its ethnobotany, traditional knowledge, and uses, but also concerning the scientific evidence regarding its phytochemical composition, pharmacological properties, and safety of its use.
Beginning with its traditional applications, which emphasize its role in treating various skin conditions, it can address numerous pathological states, irritations, wound care, or superficial infections. Interestingly, it has been found that some plant components, such as the lectins present in the seeds, can irritate and stimulate inflammatory processes in peripheral contexts and the central nervous system. However, this stimulating activity of the inflammatory response appears to contribute positively to the evolution of the healing process [13,14,16].
The ability to inhibit the growth of various Gram-positive and Gram-negative bacteria and fungi is an interesting property for treating wounds and skin infections. This effect is likely associated with the antioxidant and anti-inflammatory properties of the phenolic compounds present in the extracts, which could contribute synergistically to the treatment’s overall benefit. This multi-target pattern of drug action has been frequently explored in the search for more effective and safe therapeutic agents and appears to be the case for the Vatairea species studied [16,20,22].
In the context of diabetes, for example, the incidence of wounds and skin diseases is critical, given the difficulty in healing associated with the risk of infections that often lead to amputations, and even death. V. macrocarpa, in addition to its antimicrobial and anti-inflammatory effects and antioxidant potential, also showed benefits in diabetes models, reducing insulin resistance and glycemia. These effects can be used in isolation and synergistically [26].
Considering also the low toxicity of the extracts of V. macrocarpa and V. guianensis, it is important to advance in the pharmacological research of the Vatairea species, to elucidate their constitutions and properties in the various associated contexts and favor the development of safe and effective therapeutic agents.

Author Contributions

S.A.T.: conceptualization, formal analysis, investigation, methodology, writing—original draft; L.D.d.S.R.: formal analysis, investigation, writing—original draft; F.J.C.d.S.-J.: formal analysis, investigation, writing—original draft; B.C.d.C.: formal analysis, investigation, writing—original draft; F.C.S.G.: formal analysis, investigation, writing—original draft; L.V.P.d.S.P.: formal analysis, investigation, writing—original draft; C.S.F.M.: writing, data curation—review and editing; E.A.F.-J.: conceptualization, data curation, funding acquisition, methodology, project administration, writing—original draft, writing—review and editing. All authors have read and agreed to the published version of the manuscript.

Funding

Amazon Foundation for Research Support (FAPESPA)—scholarships to B.C.d.C., L.V.P.d.S.P. (grant number 02/2023); Foundation for the Coordination of Improvement of Higher Education Personnel (CAPES)—scholarship to S.A.T.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Braga, F.C. Brazilian traditional medicine: Historical basis, features and potentialities for pharmaceutical development. J. Tradit. Chin. Med. Sci. 2021, 8, S44–S50. [Google Scholar] [CrossRef]
  2. REFLORA. Public Search of Virtual Herbarium. Available online: https://reflora.jbrj.gov.br/reflora/herbarioVirtual/ (accessed on 29 June 2024).
  3. Miguéis, G.d.S.; da Silva, R.H.; Júnior, G.A.D.; Guarim-Neto, G. Plants used by the rural community of Bananal, Mato Grosso, Brazil: Aspects of popular knowledge. PLoS ONE 2019, 14, e0210488. [Google Scholar] [CrossRef] [PubMed]
  4. Ribeiro, R.V.; Bieski, I.G.C.; Balogun, S.O.; Martins, D.T.d.O. Ethnobotanical study of medicinal plants used by Ribeirinhos in the North Araguaia microregion, Mato Grosso, Brazil. J. Ethnopharmacol. 2017, 205, 69–102. [Google Scholar] [CrossRef]
  5. de Amorim, L.D.M.; Sousa, L.d.O.F.d.; Oliveira, F.F.M.; Camacho, R.G.V.; de Melo, J.I.M. Fabaceae na Floresta Nacional (FLONA) de Assú, semiárido potiguar, nordeste do Brasil. Rodriguésia 2016, 67, 105–124. [Google Scholar] [CrossRef]
  6. Silveira, F.S.; Miotto, S. A família Fabaceae no Morro Santana, Porto Alegre, Rio Grande do Sul, Brasil: Aspectos taxonômicos e ecológicos. Rev. Bras. Biociências 2013, 11, 93–114. [Google Scholar]
  7. Ferreira, G.C.; Gomes, J.I.; Hopkins, M.J.G. Estudo anatômico das espécies de Leguminosae comercializadas no estado do Pará como “angelim”. Acta Amaz. 2004, 34, 387–398. [Google Scholar] [CrossRef]
  8. Cardoso, D.B.O.S.; Ramos, G.; Lima, H.C. Flora e Funga do Brasil. 2020. Available online: https://floradobrasil.jbrj.gov.br/FB23208 (accessed on 29 June 2024).
  9. De Lima, H.C. Revisão Taxonômica Do Gênero Vataireopsis Ducke (LEG. FAB.). Rodriguésia 1980, 32, 21–40. [Google Scholar] [CrossRef]
  10. Tropicos. Available online: https://tropicos.org/image/101098123 (accessed on 20 December 2024).
  11. Tropicos. Available online: https://tropicos.org/image/100495992 (accessed on 20 December 2024).
  12. Plants of the World Online. Plants of the World Online|Kew Science. Available online: http://www.plantsoftheworldonline.org/ (accessed on 20 December 2024).
  13. Grenand, P.; Moretti, C.; Jacquemin, H.; Prévost, M.-F. Pharmacopées Traditionnelles en Guyane. In IRD Éditions eBooks; IRD Éditions; Elsevier: Amsterdam, The Netherlands, 2004; p. 186. [Google Scholar] [CrossRef]
  14. Filho, W. Antraquinonas de Vatairea guianensis AUBI. (FABACEAE). Available online: https://repositorio.inpa.gov.br/bitstream/1/13726/1/artigo-inpa.pdf (accessed on 29 June 2024).
  15. Araújo, G.d.M.L.d.; de Araújo, N.D.; de Farias, R.P.; Cavalcanti, F.C.N.; Lima, M.D.L.F.; Braz, R.A.F.d.S. Micoses superficiais na Paraíba: Análise comparativa e revisão literária. An. Bras. Dermatol. 2010, 85, 943–946. [Google Scholar] [CrossRef]
  16. da Silva, C.T.L.; Medeiros, B.J.S.; dos Santos, K.C.; Pereira-Filho, R.; de Albuquerque-Júnior, R.L.C.; Sousa, P.J.d.C.; Carvalho, J.C.T. Topical healing activity of the hydroethanolic extract from the seeds of Vatairea guianensis (AUBLET) Research Article. Int. J. Pharm. Sci. Rev. Res. 2011, 8, 1–8. [Google Scholar]
  17. Oliveira, A.A.; Segovia, J.F.; Sousa, V.Y.; Mata, E.C.; Gonçalves, M.C.; Bezerra, R.M.; Junior, P.O.; Kanzaki, L.I. Antimicrobial activity of amazonian medicinal plants. SpringerPlus 2013, 2, 371. [Google Scholar] [CrossRef]
  18. Ottobelli, I.; Facundo, V.A.; Zuliani, J.; Luz, C.C.; Brasil, H.O.B.; Militão, J.S.L.T.; Braz-Filho, R. Estudo químico de duas plantas medicinais da amazônia: Philodendron scabrum k. Krause (araceae) e Vatairea guianensis aubl. (fabaceae). Acta Amaz. 2011, 41, 393–400. [Google Scholar] [CrossRef]
  19. de Souza, R.F.; Marinho, V.H.S.; da Silva, G.A.; Costa-Júnior, L.M.; da Silva, J.K.R.; Bastos, G.N.T.; Arruda, A.C.; da Silva, M.N.; Arruda, M.S.P. New Isoflavones from the Leaves of Vatairea guianensis Aublé. J. Braz. Chem. Soc. 2013, 24, 1857–1863. [Google Scholar] [CrossRef]
  20. Santana, D.B.; Da Costa, R.C.; Araújo, R.M.; De Paula, J.E.; Silveira, E.R.; Filho, R.B.; Espíndola, L.S. Activity of Fabaceae species extracts against fungi and Leishmania: Vatacarpan as a novel potent anti-Candida agent. Rev. Bras. Farmacogn. 2015, 25, 401–406. [Google Scholar] [CrossRef]
  21. Mendoza-Cruz, E.; Sánchez-Gutiérrez, F.; Valdez-Hernández, J.I.; Mendoza-Cruz, E.; Sánchez-Gutiérrez, F.; Valdez-Hernández, J.I. Actividad de la guacamaya escarlata Ara macao cyanoptera (Psittaciformes: Psittacidae) y características estructurales de su hábitat en Marqués de Comillas, Chiapas. Acta Zool. Mex. 2017, 33, 169–180. [Google Scholar] [CrossRef]
  22. Souza, R.; da Silva, G.; Arruda, A.; da Silva, M.; Santos, A.; Grisólia, D.; Silva, M.; Salgado, C.; Arruda, M.S. A New Prenylisoflavone from the Antifungal Extract of Leaves of Vatairea guianensis Aubl. J. Braz. Chem. Soc. 2016, 28, 1132–1136. [Google Scholar] [CrossRef]
  23. de Jesus, N.Z.T.; Lima, J.C.d.S.; da Silva, R.M.; Espinosa, M.M.; Martins, D.T.d.O. Levantamento etnobotânico de plantas popularmente utilizadas como antiúlceras e antiinflamatórias pela comunidade de Pirizal, Nossa Senhora do Livramento-MT, Brasil. Rev. Bras. Farm. 2009, 19, 130–139. [Google Scholar] [CrossRef]
  24. dos Santos, E.; Silva-Filho, S.E.; Radai, J.A.S.; Arena, A.C.; Fraga, T.L.; Cardoso, C.A.L.; Croda, J.; Kassuya, C.A.L. Anti-inflammatory properties of ethanolic extract from Vatairea macrocarpa leaves. J. Ethnopharmacol. 2021, 278, 114308. [Google Scholar] [CrossRef] [PubMed]
  25. Costa, A.R.; Santos, A.M.; Barreto, F.S.; Costa, P.M.; Roma, R.R.; Rocha, B.A.; Oliveira, C.V.; Duarte, A.E.; Pessoa, C.; Teixeira, C.S. In vitro antiproliferative effects of Vatairea macrocarpa (Benth.) Ducke lectin on human tumor cell lines and in vivo evaluation of its toxicity in Drosophila melanogaster. Food Chem. Toxicol. 2024, 190, 114815. [Google Scholar] [CrossRef]
  26. Oliveira, H.C.; dos Santos, M.P.; Grigulo, R.; Lima, L.L.; Martins, D.T.; Lima, J.C.; Stoppiglia, L.F.; Lopes, C.F.; Kawashita, N.H. Antidiabetic activity of Vatairea macrocarpa extract in rats. J. Ethnopharmacol. 2008, 115, 515–519. [Google Scholar] [CrossRef]
  27. Baviloni, P.D.; dos Santos, M.P.; Aiko, G.M.; Reis, S.R.d.L.; Latorraca, M.Q.; da Silva, V.C.; Dall’oglio, E.L.; Júnior, P.T.d.S.; Lopes, C.F.; Baviera, A.M.; et al. Mechanism of anti-hyperglycemic action of Vatairea macrocarpa (Leguminosae): Investigation in peripheral tissues. J. Ethnopharmacol. 2010, 131, 135–139. [Google Scholar] [CrossRef]
  28. Eddouks, M.; Bidi, A.; El Bouhali, B.; Hajji, L.; Zeggwagh, N.A. Antidiabetic plants improving insulin sensitivity. J. Pharm. Pharmacol. 2014, 66, 1197–1214. [Google Scholar] [CrossRef]
  29. Simatupang, M.H.; Dietrichs, H.H.; Gottwald, H. Über die hautreizenden Stoffe in Vatairea guianensis Aubl. Holzforschung 1967, 21, 89–94. [Google Scholar] [CrossRef]
  30. de Souza, R.F.; da Silva, J.K.R.; da Silva, G.A.; Arruda, A.C.; da Silva, M.N.; Arruda, M.S.P. Chemical Study and Evaluation of the Antioxidant Potential of Sapwood of Vatairea guianensis Aubl. Rev. Virtual Quim. 2015, 7, 1893–1906. [Google Scholar] [CrossRef]
  31. Formiga, M.D.; Gottlieb, O.R.; Mendes, P.H.; Koketsu, M.; de Almieda, M.L.; Pereira, M.O.d.S.; Magalhães, M.T. Constituents of Brazilian leguminosae. Phytochemistry 1975, 14, 828–829. [Google Scholar] [CrossRef]
  32. Sehgal, V.N.; Verma, P.; Khurana, A. Anthralin/dithranol in dermatology. Int. J. Dermatol. 2014, 53, e449–e460. [Google Scholar] [CrossRef] [PubMed]
  33. Carvalho, P.O.; Campos, P.R.b.; Noffs, M.A.; Oliveira, J.G.; Shimizu, M.T.; da Silva, D.M. Application of microbial lipases to concentrate polyunsaturated fatty acids. Química Nova 2003, 26, 75–80. [Google Scholar] [CrossRef]
  34. Vandenborre, G.; Smagghe, G.; Van Damme, E.J. Plant lectins as defense proteins against phytophagous insects. Phytochemistry 2011, 72, 1538–1550. [Google Scholar] [CrossRef]
  35. Gemeiner, P.; Mislovičová, D.; Tkáč, J.; Švitel, J.; Pätoprstý, V.; Hrabárová, E.; Kogan, G.; Kožár, T. Lectinomics. Biotechnol. Adv. 2009, 27, 1–15. [Google Scholar] [CrossRef]
  36. Zwierzina, H.; Bergmann, L.; Fiebig, H.; Aamdal, S.; Schöffski, P.; Witthohn, K.; Lentzen, H. The preclinical and clinical activity of aviscumine: A potential anticancer drug. Eur. J. Cancer 2011, 47, 1450–1457. [Google Scholar] [CrossRef]
  37. Bies, C.; Lehr, C.-M.; Woodley, J.F. Lectin-mediated drug targeting: History and applications. Adv. Drug Deliv. Rev. 2003, 56, 425–435. [Google Scholar] [CrossRef]
  38. Silva, H.C.; Nagano, C.S.; Souza, L.A.; Nascimento, K.S.; Isídro, R.; Delatorre, P.; Rocha, B.A.M.; Sampaio, A.H.; Assreuy, A.M.S.; Pires, A.F.; et al. Purification and primary structure determination of a galactose-specific lectin from Vatairea guianensis Aublet seeds that exhibits vasorelaxant effect. Process. Biochem. 2012, 47, 2347–2355. [Google Scholar] [CrossRef]
  39. Cavada, B.S.; Osterne, V.J.S.; Pinto-Junior, V.R.; Souza, L.A.G.; Lossio, C.F.; Silva, M.T.L.; Correia-Neto, C.; Oliveira, M.V.; Correia, J.L.A.; Neco, A.H.B.; et al. Molecular dynamics and binding energy analysis of Vatairea guianensis lectin: A new tool for cancer studies. J. Mol. Model. 2020, 26, 22. [Google Scholar] [CrossRef]
  40. Vasconcelos, M.A.; Arruda, F.V.S.; Carneiro, V.A.; Silva, H.C.; Nascimento, K.S.; Sampaio, A.H.; Cavada, B.; Teixeira, E.H.; Henriques, M.; Pereira, M.O. Effect of Algae and Plant Lectins on Planktonic Growth and Biofilm Formation in Clinically Relevant Bacteria and Yeasts. BioMed Res. Int. 2014, 2014, 365272. [Google Scholar] [CrossRef]
  41. Teixeira, E.; Napimoga, M.; Carneiro, V.; de Oliveira, T.; Cunha, R.; Havt, A.; Martins, J.; Pinto, V.; Goncalves, R.; Cavada, B. In vitro inhibition of Streptococci binding to enamel acquired pellicle by Plant Lectins. J. Appl. Microbiol. 2006, 101, 111–116. [Google Scholar] [CrossRef]
  42. Santos, V.F.; Costa, M.S.; Campina, F.F.; Rodrigues, R.R.; Santos, A.L.E.; Pereira, F.M.; Batista, K.L.R.; Silva, R.C.; Pereira, R.O.; Rocha, B.A.M.; et al. The Galactose-Binding Lectin Isolated from Vatairea macrocarpa Seeds Enhances the Effect of Antibiotics Against Staphylococcus aureus–Resistant Strain. Probiotics Antimicrob. Proteins 2019, 12, 82–90. [Google Scholar] [CrossRef]
  43. Véras, J.H.; Cardoso, C.G.; Puga, S.C.; Bisneto, A.V.d.M.; Roma, R.R.; Silva, R.R.S.; Teixeira, C.S.; Chen-Chen, L. Lactose-binding lectin from Vatairea macrocarpa seeds induces in vivo angiogenesis via VEGF and TNF-ɑ expression and modulates in vitro doxorubicin-induced genotoxicity. Biochimie 2022, 194, 55–66. [Google Scholar] [CrossRef] [PubMed]
  44. Jesus, N.Z.T.; Júnior, I.F.S.; Lima, J.C.S.; Colodel, E.M.; Martins, D.T.O. Hippocratic screening and subchronic oral toxicity assessments of the methanol extract of Vatairea macrocarpa heartwood in rodents. Rev. Bras. Farm. 2012, 22, 1308–1314. [Google Scholar] [CrossRef]
  45. da Silva, C.T.L.; Mendonça, L.C.; Chagas Monteiro, M.; Carvalho, J.C.T. Antimicrobial activity of extracts obtained from the seeds of Vatairea guianensis (Aublet). Bol. Latinoam. Caribe Plantas Med. Aromát. 2011, 10, 456–462. [Google Scholar]
  46. Monteiro, A.M.O.; Havt, A.; Barbosa, P.S.F.; Soares, T.F.; Evangelista, J.S.A.M.; Alencar, N.M.N.; Monteiro, H.S.A.; Martins, A.M.C.; de Menezes, D.B.; Fonteles, M.C.; et al. Renal effects induced by the lectin from Vatairea macrocarpa seeds. J. Pharm. Pharmacol. 2005, 57, 1329–1333. [Google Scholar] [CrossRef]
  47. Alencar, N.M.; Assreuy, A.M.; Alencar, V.B.; Melo, S.C.; Ramos, M.V.; Cavada, B.S.; Cunha, F.Q.; Ribeiro, R.A. The galactose-binding lectin from Vatairea macrocarpa seeds induces in vivo neutrophil migration by indirect mechanism. Int. J. Biochem. Cell Biol. 2003, 35, 1674–1681. [Google Scholar] [CrossRef]
  48. Alencar, N.M.N.; Assreuy, A.M.S.; Havt, A.; Benevides, R.G.; de Moura, T.R.; de Sousa, R.B.; Ribeiro, R.A.; Cunha, F.Q.; Cavada, B.S. Vatairea macrocarpa (Leguminosae) lectin activates cultured macrophages to release chemotactic mediators. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2006, 374, 275–282. [Google Scholar] [CrossRef] [PubMed]
  49. Marques, G.F.; Osterne, V.J.; Almeida, L.M.; Oliveira, M.V.; Brizeno, L.A.; Pinto-Junior, V.R.; Santiago, M.Q.; Neco, A.H.; Mota, M.R.; Souza, L.A.; et al. Contribution of the carbohydrate-binding ability of Vatairea guianensis lectin to induce edematogenic activity. Biochimie 2017, 140, 58–65. [Google Scholar] [CrossRef]
  50. Gonçalves, F.M.; Freitas, A.E.; Peres, T.V.; Rieger, D.K.; Ben, J.; Maestri, M.; Costa, A.P.; Tramontina, A.C.; Gonçalves, C.A.; Rodrigues, A.L.S.; et al. Vatairea macrocarpa Lectin (VML) Induces Depressive-like Behavior and Expression of Neuroinflammatory Markers in Mice. Neurochem. Res. 2013, 38, 2375–2384. [Google Scholar] [CrossRef] [PubMed]
  51. Leite, G.d.O.; Santos, S.A.A.R.; Bezerra, F.M.D.H.; de Silva, F.E.S.; Ribeiro, A.D.d.C.; Roma, R.R.; Silva, R.R.S.; Santos, M.H.C.; Santos, A.L.E.; Teixeira, C.S.; et al. Is the orofacial antinociceptive effect of lectins intrinsically related to their specificity to monosaccharides? Int. J. Biol. Macromol. 2020, 161, 1079–1085. [Google Scholar] [CrossRef] [PubMed]
  52. Araújo, J.R.C.; Coelho, C.B.; Campos, A.R.; Moreira, R.d.A.; Monteiro-Moreira, A.C.d.O. Animal Galectins and Plant Lectins as Tools for Studies in Neurosciences. Curr. Neuropharmacol. 2020, 18, 202–215. [Google Scholar] [CrossRef]
  53. Fosso, M.Y.; Chan, K.Y.; Gregory, R.; Chang, C.-W.T. Library Synthesis and Antibacterial Investigation of Cationic Anthraquinone Analogs. ACS Comb. Sci. 2012, 14, 231–235. [Google Scholar] [CrossRef]
  54. Liu, X.; Hu, H.; Liu, J.; Chen, J.; Chu, J.; Cheng, H. Physcion, a novel anthraquinone derivative against Chlamydia psittaci infection. Vet. Microbiol. 2023, 279, 109664. [Google Scholar] [CrossRef]
  55. Comini, L.R.; Vieyra, F.E.M.; Mignone, R.A.; Páez, P.L.; Mugas, M.L.; Konigheim, B.S.; Cabrera, J.L.; Montoya, S.C.N.; Borsarelli, C.D. Parietin: An efficient photo-screening pigment in vivo with good photosensitizing and photodynamic antibacterial effects in vitro. Photochem. Photobiol. Sci. 2016, 16, 201–210. [Google Scholar] [CrossRef]
  56. García-Sosa, K.; Villareal-Alvarez, N.; Lübben, P.; Peña-Rodríguez, L.M. Chrysophanol, an Antimicrobial Anthraquinone from the Root Extract of Colubrina greggii. J. Mex. Chem. Soc. 2020, 50, 76–78. [Google Scholar] [CrossRef]
  57. Fonseca, S.; dos Santos, N.S.S.; Torres, A.; Siqueira, M.; da Cunha, A.; Manzoni, V.; Provasi, P.F.; Gester, R.; Canuto, S. Role of the Solvent and Intramolecular Hydrogen Bonds in the Antioxidative Mechanism of Prenylisoflavone from Leaves of Vatairea guianensis. J. Phys. Chem. A 2023, 127, 10807–10816. [Google Scholar] [CrossRef]
  58. Santos, J.V.d.O.; Porto, A.L.F.; Cavalcanti, I.M.F. Potential Application of Combined Therapy with Lectins as a Therapeutic Strategy for the Treatment of Bacterial Infections. Antibiotics 2021, 10, 520. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Photographs of the Vatairea species. The images of V. erythrocarpa, V. fusca, V. guianensis, V. heteroptera, and V. macrocarpa were provided by Domingos Cardoso and are sourced from the Reflora website [2]. The photograph of V. paraensis is credited to L. O. A. Teixeira, also from the Reflora website [2]. Images of V. lundelli and V. sericea were obtained from the Trópicos website, with photos by Aguilar Fernandez [10] and MBG [11].
Figure 1. Photographs of the Vatairea species. The images of V. erythrocarpa, V. fusca, V. guianensis, V. heteroptera, and V. macrocarpa were provided by Domingos Cardoso and are sourced from the Reflora website [2]. The photograph of V. paraensis is credited to L. O. A. Teixeira, also from the Reflora website [2]. Images of V. lundelli and V. sericea were obtained from the Trópicos website, with photos by Aguilar Fernandez [10] and MBG [11].
Pharmaceuticals 18 00422 g001
Figure 2. Popular names, preparation, traditional uses, and geographical distribution of Vatairea sp.
Figure 2. Popular names, preparation, traditional uses, and geographical distribution of Vatairea sp.
Pharmaceuticals 18 00422 g002
Table 1. Phytochemical aspects of Vatairea genus.
Table 1. Phytochemical aspects of Vatairea genus.
SpeciesCollection SitesPlant PartsType of ExtractionPhytoconstituents IdentifiedReference
V. guianensisUnspecifiedHeartwoodHot extraction
Solvent: benzene
Chrysophanic acid-9-anthrone, physcion-9-anthrone and physcion-10-anthrone[29]
Ilha do Marapatá,
Manaus—Brazil
Stem barkSoxhlet extraction.
Solvent: ethanol
Chrysophanol, physcion, emodin, and triterpenes[14]
Parque Ecológico de Porto Velho, Rondônia—BrazilFruitsEssential oil
hydrodistillation with ethanol
Aldehydes (hexanal, (2Z)-heptenal, (2E,4E)-decadienal, undecenal, dodecanal) and carboxylic acids (docosahexaenoic acid, hexadecanoic acid, and stearic acid)[18]
Belém, Pará—BrazilLeavesMaceration extraction;
Solvent: ethanol
Chrysophanol and physcion[19]
Maceration extraction;
Solvent: ethanol
5,3′-dihydroxy-4′-methoxy-2″,2″-dimethylpyrano-(5″,6″:8,7)-isoflavone; 5,7-dihydroxy-3′,4′-methylenedioxy-8-prenyl-isoflavone; 5,3′-dihydroxy-4′-methoxy-7-O-β-glucopyranoside-8-prenyl-isoflavone; and derrone
Belém, Pará—BrazilSapwoodMaceration extraction;
Solvent: ethanol
Crysophanol, physcion, formononetin, bolusantol D, betulinic acid, sitosterol, and stigmasterol[30]
Belém, Pará—BrazilLeavesMaceration extraction;
Solvent: ethanol
5,7,3′-trihydroxy-4′-methoxy-8-prenyl-isoflavone; upiwighteone; and 5,7,4′-trihydroxy-3′-methoxy-8-prenyl isoflavone[22]
V. heteropteraLinhares Forest Reserve, Rio Doce, Espírito Santo—BrazilTrunk woodMaceration extraction;
Solvent: benzene
Chrysophanol, sitosterol, stigmasterol, emodin, (2S)-7-hydroxiflavone, and formononetin[31]
V. macrocarpaCampo Grande, Mato Grosso—BrazilLeavesMaceration extraction;
Solvent: ethanol
Catechin, epicatechin, kaempferol-3-O-α-l-rhamnopyranoside, tannins[24]
Table 2. Pharmacological properties of Vatairea genus.
Table 2. Pharmacological properties of Vatairea genus.
Experimental ModelSpecieExtract (Part)Dose/Concentration (via)Key OutcomesRef.
Toxicity Studies
In vitro toxicity
  Leukocyte viability (mice)V. macrocarpaEthanolic (leaves)3–90 μg/mLNo cytotoxicity (MTT).[24]
  Lymphocyte culture (human)V. macrocarpaLectin (seed)0.5–45 µMTrypan blue assay—concentration-dependent cytotoxicity (≥1 µM)[43]
0.5–8 µMComet assay:
8 µM—increases DNA damage
0.5–2 µM—decreases doxorubicin-induced DNA damage
In vivo toxicity
  Acute (male mice)V. guianensisHydroethanolic (seed)2000 and 5000 mg/kg (oral)No signals of toxicity, or death. LD50 > 5000 mg/kg[16]
V. macrocarpaMethanolic (heartwood)100–5000 mg/kg (oral)No behavioral changes, or death. LD50 > 5000 mg/kg[44]
Ethanolic (stembark)250–5000 mg/kg (oral)No signals of toxicity, or death. LD50 > 5000 mg/kg[26]
  Subchronic 30 days (male rats)V. macrocarpaMethanolic (heartwood)20–500 mg/kg (oral)No behavioral, anatomical, or histological changes, either death
↑ Segmented neutrophils (500 mg/kg).
↑ Alkaline phosphatase
↑ Plasma protein
↓ γ-glutamyl transferase (100 mg/kg).
↓ Triacylglyceride
[44]
Communicable diseases
In vitro antibacterial test
  Enterococcus faecalisV. guianensisHydroalcoholic (seed)
Hexane (seed)
Chloroform (seed)
Methanolic (seed)
0.4–100 μg/mLMIC 12.5 μg/mL; MBC 25 μg/mL
MIC 12.5 μg/mL; MBC 25 μg/mL
MIC 3.12 μg/mL; MBC 12.5 μg/mL
MIC 12.5 μg/mL; MBC 50 μg/mL
[45]
  Escherichia coli V. macrocarpaLectin (seed)1.0–1024 μg/mLNo antibiotic activity (MIC ≥ 1024 μg/mL)
Decrease norfloxacin antibiotic activity
[42]
  Klebsiella oxytocaV. macrocarpaLectin (seed)31.25–250 μg/mLNo antibiotic activity (MIC > 250 μg/mL)[40]
  Pseudomonas aeruginosaV. macrocarpaLectin (seed)31.25–250 μg/mLWeakly inhibition of planktonic growth (250 μg/mL).[40]
V. guianensisHydroalcoholic (seed)
Hexane (seed)
Chloroform (seed)
Methanolic (seed)
0.4–100 μg/mLMIC 25 μg/mL; MBC 100 μg/mL
MIC 25 μg/mL; MBC 100 μg/mL
MIC 25 μg/mL; MBC 100 μg/mL
MIC 25 μg/mL; MBC 50 μg/mL
[45]
  Salmonella sp.V. guianensisHydroalcoholic (seed)
Hexane (seed)
Chloroform (seed)
Methanolic (seed)
0.4–100 μg/mLNo activity
No activity
MIC 50 μg/mL; MBC 100 μg/mL
MIC 50 μg/mL; MBC 100 μg/mL
[45]
  Staphylococcus aureusV. guianensisAqueous (leaves)2.275 mg/mL (30 μL/hole)Antibacterial activity at 44.4% of ciprofloxacin (agar diffusion test).[17]
Hydroalcoholic (seed)
Hexane (seed)
Chloroform (seed)
Methanolic (seed)
0.4–100 μg/mLMIC 3.12 μg/mL; MBC 6.25 μg/mL
MIC 6.25 μg/mL; MBC 12.5 μg/mL
MIC 3.12 μg/mL; MBC 12.5 μg/mL
MIC 6.25 μg/mL; MBC 12.5 μg/mL
[45]
V. macrocarpaLectin (seed)1.0–1024 μg/mLNo antibiotic activity (MIC ≥ 1024 μg/mL)
Increase in norfloxacin, penicillin, and gentamicin antibiotic activity
[42]
V. macrocarpaLectin (seed)31.25–250 μg/mLComplete inhibition of planktonic growth (250 μg/mL)
Inhibition of biomass formation in biofilms
Decrease in the number of viable cells in the biofilm
[40]
  S. epidermidisV. macrocarpaLectin (seed)31.25–250 μg/mLComplete inhibition of planktonic growth (250 μg/mL)
Influence in biofilm formation
Decrease in the number of viable cells in the biofilm
[40]
  Streptococcus sanguisV. macrocarpaLectin (seed)100 μg/mLInhibition of bacterial adhesion to the acquired pellicle on tooth enamel[41]
In vivo antibacterial test
  Mycobacterium bovisV. macrocarpaEthanolic (leaves)30–300 mg/kgAntimycobacterial activity[24]
In vitro antifungal test
  Candida albicansV. macrocarpaEthyl acetate (root bark)
Vatacarpan (root bark)
-MIC 0.98 µg/mL
MIC 0.98 µg/mL
[20]
Lectin (seed)31.25–250 µg/mLWeakly inhibition of planktonic growth (250 µg/mL)[40]
V. guianensisEthanolic extract (leaves)
Hexanic fraction
Ethyl acetate fraction
Methanol/H2O fraction
0.125–1024 µg/mLMIC 128 µg/mL; MFC 512 µg/mL
No activity
MIC 16 µg/mL; MFC 32 µg/mL.
No activity
[22]
5,7,3′-trihydroxy-4′-methoxy-8-prenylisoflavone0.125–256 µg/mLNo activity
  C. dubliniensisV. guianensisEthanolic extract (leaves)
Hexanic fraction
Ethyl acetate fraction
Methanol/H2O fraction
0.125–1024 µg/mLMIC 32 µg/mL
MIC 64 µg/mL
MIC 8 µg/mL; MFC 16 µg/mL
No activity
[22]
5,7,3′-trihydroxy-4′-methoxy-8-prenylisoflavone0.125–256 µg/mLMIC 8 µg/mL
  C. kruseiV. guianensisEthanolic extract (leaves)
Hexanic fraction
Ethyl acetate fraction
Methanol/H2O fraction
0.125–1024 µg/mLMIC 128 µg/mL
MIC 512 µg/mL; MFC 512 µg/mL
MIC 8 µg/mL; MFC 32 µg/mL
No activity
[22]
5,7,3′-trihydroxy-4′-methoxy-8-prenylisoflavone0.125–256 µg/mLNo activity
  C. parapsilosisV. macrocarpaEthyl acetate-MIC 0.98 µg/mL[20]
V. guianensisEthanolic extract (leaves)
Hexanic fraction
Ethyl acetate fraction
Methanol/H2O fraction
No activity
MIC 64 µg/mL
MIC 8 µg/mL; MFC 32 µg/mL
No activity
[22]
5,7,3′-trihydroxy-4′-methoxy-8-prenylisoflavone0.125–256 µg/mLMIC 32 µg/mL
In vitro antiprotozoal test
  Leishmania amazonensisV. macrocarpaEthyl acetate (root bark)-Antileishmanial activity (IC50 71.47 µg/mL)[20]
Non-communicable diseases
Endocrine system
  Type 2 diabetes (streptozotocin; male rats)V. macrocarpaEthanolic (stembark)250 and 500 mg/kg
(oral, 22 days)
Reductions observed include postprandial glycemia, food and fluid intake, urinary volume, and the excretion of glucose and urea in urine
Improvement in weight gain
Reduction in HOMA-R index
[26]
500 mg/kg (oral, 21 days)Increase insulin receptor and AKT phosphorylation in the liver, extensor digitorum longus muscles, and retroperitoneal white adipose tissue[27]
Cardiovascular and renal systems
  Ex vivo aortic contraction (rat)V. guianensisLectin (seed)1–100 μg/mLConcentration-dependent relaxation of phenylephrine-induced aortic contraction
This effect appears to involve the release of nitric oxide (NO) by the vascular endothelium
Galactose abolishes the lectin’s vasorelaxant effect
[38]
  In situ kidney perfusion (rat)V. macrocarpaLectin (seed)10 μg/mLIncrease perfusion pressure, renal vascular resistance, urinary flow, and glomerular filtration rate
Galactose abolishes the lectin’s kidney effect
Moderate protein buildup in tubules and urinary spaces
Renal tubules with eosinophilic casts
[46]
  Angiogenic activity
  Embryo chorioallantoic membrane (chicken)
V. macrocarpaLectin (seed)0.5–8 μM↑ Vascularization and number of blood vessels (angiogenesis)
↑ Length, size, number of complexes, and blood vessel junctions
↑ Inflammatory cells and fibroblasts
↑ Thickening of CAM
↑ VEGF and TNF-α expression
Lactose reduced the lectin’s effects
[43]
Immune system
  In vitro inflammation
  Neutrophil phagocytic activityV. macrocarpaEthanolic (leaves)3–30 μg/mLReduction in neutrophil phagocytic activity[24]
  In vivo inflammation
  Carrageenan-induced pleurisy, BCG-induced pleurisy, CFA-induced paw edemaV. macrocarpaEthanolic (leaves)10–300 mg/kg (oral)Dose-dependent reduction in leukocyte migration and protein concentration in pleural exudate
CFA-induced paw edema: no effect in hyperalgesia, reduction in paw edema, and cold sensitivity
[24]
  Neutrophil migration (female rat) V. macrocarpaLectin (seed)9.6 × 10−7, 1.9 × 10−6, or
3.8 × 10−6 M (1 mL, intraperitoneal)
Neutrophil and mononuclear cell migration to the peritoneal cavity is induced in a dose-dependent manner through macrophage-mediated mechanisms (cytokine release)
Galactose abolishes the lectin’s proinflammatory effect, suggesting it acts via its carbohydrate-binding site.
[47]
V. macrocarpaLectin (seed)4.8 × 10−7, 9.6 × 10−7, or 1.9 × 10−6 mol Lectin induces cultured macrophages to release a neutrophil chemotactic mediator[48]
  Paw edema (rat)V. guianensisLectin (seed)0.01, 0.1, and 1 mg/kgTime- and dose-dependent paw edema, with polymorphonuclear infiltrate
Indomethacin (COX blocker) partially inhibits this effect, but L-NAME (NOS inhibitor) does not
[49]
Central nervous system
  Neuroinflammation (male mice)V. macrocarpaLectin (seed)0.3–3 μg/site (intracerebroventricular)Depressive-like effect (forced swimming test)
Proinflammatory effect in the hippocampus: (↑ COX-2, GFAP, and S100B)
[50]
Nociception
  Orofacial nociception (zebrafish)V. macrocarpaLectin (seed)0.025, 0.05 or 0.1 mg/mL
(20 μL; intraperitoneal)
No pain relief effect[51]
Wound-healing
  Dorsal wound (rat)V. guianensisHydroethanolic (seed)100–500 mg/kg (topical)Improve wound contraction from the third day of treatment (100 mg/kg)
Inflammatory response reduction
Stimulation of collagen synthesis
[16]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Toledo, S.A.; Reis, L.D.d.S.; da Conceição, B.C.; Pantoja, L.V.P.d.S.; de Souza-Junior, F.J.C.; Garcez, F.C.S.; Maia, C.S.F.; Fontes-Junior, E.A. Vatairea Genus as a Potential Therapeutic Agent—A Comprehensive Review of Ethnobotanical, Phytochemical, and Pharmacological Properties. Pharmaceuticals 2025, 18, 422. https://doi.org/10.3390/ph18030422

AMA Style

Toledo SA, Reis LDdS, da Conceição BC, Pantoja LVPdS, de Souza-Junior FJC, Garcez FCS, Maia CSF, Fontes-Junior EA. Vatairea Genus as a Potential Therapeutic Agent—A Comprehensive Review of Ethnobotanical, Phytochemical, and Pharmacological Properties. Pharmaceuticals. 2025; 18(3):422. https://doi.org/10.3390/ph18030422

Chicago/Turabian Style

Toledo, Sarah Andrade, Laryssa Danielle da Silva Reis, Brenda Costa da Conceição, Lucas Villar Pedrosa da Silva Pantoja, Fábio José Coelho de Souza-Junior, Flávia Cristina Santos Garcez, Cristiane Socorro Ferraz Maia, and Eneas Andrade Fontes-Junior. 2025. "Vatairea Genus as a Potential Therapeutic Agent—A Comprehensive Review of Ethnobotanical, Phytochemical, and Pharmacological Properties" Pharmaceuticals 18, no. 3: 422. https://doi.org/10.3390/ph18030422

APA Style

Toledo, S. A., Reis, L. D. d. S., da Conceição, B. C., Pantoja, L. V. P. d. S., de Souza-Junior, F. J. C., Garcez, F. C. S., Maia, C. S. F., & Fontes-Junior, E. A. (2025). Vatairea Genus as a Potential Therapeutic Agent—A Comprehensive Review of Ethnobotanical, Phytochemical, and Pharmacological Properties. Pharmaceuticals, 18(3), 422. https://doi.org/10.3390/ph18030422

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop